Slavisa Gasic
Hematology & Oncology · San Antonio, TXNPI 1558403337
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 130 payments — averaging $24.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$576
- Pfizer$287
- Novartis$193
- Astellas Pharma US Inc$189
- Incyte Corporation$172
- Merck$143
- plus $2K from 30 others
Across 2 payments — averaging $15,121 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$30K
What the payments were for
- Food & beverage$2,94193%
- Education$2317%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $576 |
| Pfizer | 14 | $287 |
| Novartis | 12 | $193 |
| Astellas Pharma US Inc | 7 | $189 |
| Incyte Corporation | 4 | $172 |
| Merck | 9 | $143 |
| Boehringer Ingelheim | 2 | $143 |
| E.r. Squibb & Sons, L.L.C. | 12 | $135 |
| AbbVie | 2 | $121 |
| AVEO Pharmaceuticals, Inc. | 2 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $110 |
| Tesaro, Inc. | 1 | $88 |
| Lilly USA, LLC | 5 | $74 |
| Regeneron Healthcare Solutions, Inc. | 2 | $71 |
| Sanofi | 3 | $67 |
| Genentech USA, Inc. | 3 | $66 |
| Eisai Inc. | 3 | $61 |
| Bayer | 4 | $60 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Exelixis Inc. | 2 | $47 |
| Amgen | 3 | $46 |
| Johnson & Johnson | 3 | $43 |
| Tersera Therapeutics LLC | 2 | $41 |
| Coherus Oncology, Inc. | 1 | $31 |
| AMAG Pharmaceuticals, Inc. | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Seagen Inc. | 2 | $26 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Caris MPI, Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Verastem, Inc. | 1 | $14 |
| EMD Serono, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,172 in reported general payments places this provider in the 45th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in San Antonio
- Timothy FenskeSan Antonio$626K
- Paul ShaughnessySan Antonio$470K
- Adolfo DiazSan Antonio$463K
- Francis GilesSan Antonio$436K
- John RenshawSan Antonio$430K
- Marcela Mazo-CanolaSan Antonio$257K
- Elizabeth Bowhay-CarnesSan Antonio$204K
- Nosha FarhadfarSan Antonio$117K
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.